Skip to main content
Equibles

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

Position in TSHA — Taysha Gene Therapies, Inc.

CIK 861177 NEW YORK, NY
Back to TSHA Full portfolio

Position in TSHA

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$1,856,404
+$668,301 QoQ
Shares Held
272,600
+2.6% QoQ
Ownership
0.084%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#73
of 208 holders
Holding Since
Sep 2020
4 quarters on record
Voting authority Sole 28% Shared 0% None 72%

Common Shares in TSHA Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC holds $4,443,898,601 across 206 Biotechnology names. TSHA ranks #104 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 3,086,683 $1,533,248,041
2 REGN
Regeneron Pharmaceuticals, Inc.
 716,560 $446,803,817
3 ALNY
Alnylam Pharmaceuticals, Inc.
 727,848 $219,104,078
4 INCY
Incyte Corp
 1,508,720 $171,028,494
5 RVMD
Revolution Medicines, Inc.
 912,335 $170,862,094
6 INSM
INSMED Inc
 1,335,071 $142,345,265
7 IONS
Ionis Pharmaceuticals Inc
 1,454,672 $115,340,938
8 MRNA
Moderna, Inc.
 1,521,849 $106,575,080

All Filings in TSHA

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $1,856,404 272,600
2026-03-31 $1,188,103 265,795
2025-12-31 $921,250 167,500
2020-09-30 $4,480,000 200,000